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Abstract
Background: We previously demonstrated that cyclooxygenase (COX)-1 deficiency results in greater morbidity and
inflammation, whereas COX-2 deficiency leads to reduced morbidity, inflammation and mortality in influenza infected mice.
Methodology/Principal Findings: We investigated the effects of COX-1 and COX-2 inhibitors in influenza A viral infection.
Mice were given a COX-1 inhibitor (SC-560), a COX-2 inhibitor (celecoxib) or no inhibitor beginning 2 weeks prior to
influenza A viral infection (200 PFU) and throughout the course of the experiment. Body weight and temperature were
measured daily as indicators of morbidity. Animals were sacrificed on days 1 and 4 post-infection and bronchoalveolar
lavage (BAL) fluid was collected or daily mortality was recorded up to 2 weeks post-infection. Treatment with SC-560
significantly increased mortality and was associated with profound hypothermia and greater weight loss compared to
celecoxib or control groups. On day 4 of infection, BAL fluid cells were modestly elevated in celecoxib treated mice
compared to SC-560 or control groups. Viral titres were similar between treatment groups. Levels of TNF-a and G-CSF were
significantly attenuated in the SC-560 and celecoxib groups versus control and IL-6 levels were significantly lower in BAL
fluid of celecoxib treated mice versus control and versus the SC-560 group. The chemokine KC was significantly lower in SC-
560 group versus control.
Conclusions/Significance: Treatment with a COX-1 inhibitor during influenza A viral infection is detrimental to the host
whereas inhibition of COX-2 does not significantly modulate disease severity. COX-1 plays a critical role in controlling the
thermoregulatory response to influenza A viral infection in mice.
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Introduction
Seasonal influenza is a major cause of morbidity and mortality
worldwide. The outbreak of highly pathogenic H5N1 avian
influenza in 2003 and the recent emergence of a new triple-
reassortant influenza A (H1) virus — containing genes from avian,
human, and swine influenza viruses [1] —are important reminders
of the public health and clinical challenges posed by influenza
viruses. Because of antigenic drift and shift of influenza viruses,
new epidemics are difficult to prevent or control and vaccines need
to be updated annually [2,3]. There is a clear need for effective
alternative or complementary therapies to vaccines and antiviral
agents. A better understanding of the endogenous regulatory
pathways modulating host response may pave the way for better
therapies in the future.
Previous studies have suggested that dysregulation of the host
inflammatory response to influenza may contribute to disease
severity [4,5]. Many severe infections are characterized by
excessive inflammation and elevated pro-inflammatory cytokines
and chemokines, a phenomenon known as hypercytokinemia or
‘‘cytokine storm.’’ Such findings have prompted suggestions that
immunomodulatory and anti-inflammatory agents might be
effective for treatment and prophylaxis of influenza [6–8].
The cyclooxygenase (COX) enzymes, which catalyze the
conversion of arachidonic acid into prostaglandins, play a significant
role in modulating inflammation and immune responses [9–14].
COX inhibitors are used clinically for their anti-inflammatory,
analgesic and anti-pyretic properties and include the conventional
non-selective non-steroidal anti-inflammatory drugs (NSAIDs) (e.g.
ibuprofen) and COX-2 selective inhibitors (e.g. celecoxib).
We previously found that COX-1 deficiency is detrimental
whereas COX-2 deficiency is beneficial to the host in response to
influenza A virus; infection induced less severe illness in COX-
2
–/– mice compared to WT and COX-1
–/– mice, and
inflammation was elevated in the COX-1
–/– mice but amelio-
rated in the COX-2
–/– mice [11]. These findings suggest
important but somewhat contrasting roles for both COX isoforms
in the host response to influenza A virus. The effects of selective
pharmacologic inhibitiors of COX-1 or COX 2 in this model
have not been investigated. Hence, the objective of the present
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11610study was to examine the effects of pharmacologic inhibition of
COX-1 or COX-2 on the host response to acute influenza A viral
infection in mice.
Results
Clinical signs of infection
By day 10 of infection, 100% of the SC-560 group had
succumbed to the illness. In contrast, on day 10, there were
significantly more survivors in the no inhibitor and celecoxib
treated groups where only 70% and 68%, respectively, succumbed
to infection (p,0.05) (Figure 1).
Body temperature increased slightly in the control group on day
1 of infection (Figure 2). From days 2 to 6, mice in this group
became progressively hypothermic. After day 6, body temperature
stabilized in surviving animals and trended upwards toward pre-
infection levels through day 14 post-infection. The temperature
profile of celecoxib treated mice was similar to that of control mice
except that on day 1, body temperature had already dropped in
the celecoxib treated group and was significantly lower than the
control group. Body temperature also dropped in the SC-560
treated mice on day 1 of infection; however, compared to control
and celecoxib treated groups, body temperature dropped at a
more rapid rate in the SC-560 group from days 1 to 9 post-
infection (Figure 2).
The control group began to lose weight on day 1 post-infection
and progressively lost more weight until day 7 when surviving
animals in this group began to regain weight (Figure 3). A similar
pattern of weight change was observed in the celecoxib treated
group; although there tended to be greater weight loss in the
celecoxib group versus the control group, the differences were
not statistically significant. SC-560 treated mice lost weight at a
similar rate to the control and celecoxib groups until day 7 post-
infection when the SC-560 group began to rapidly lose weight
until day 10 when there were no surviving animals left in this
group (Figure 3).
Taken together, these data demonstrate that COX-1 inhibition,
but not COX-2 inhibition, results in increased mortality, more
severe hypothermia and increased weight loss following influenza
A viral infection.
BAL fluid inflammatory cells
In all three groups on day 1 post-infection, BAL fluid contained
mainly macrophages with a small number of infiltrating
neutrophils (Figure 4, Table 1). On day 4 post-infection, BAL
fluid cell influx increased in all three groups; however, there was a
modest but statistically significant elevation in absolute numbers of
total cells and neutrophils in BAL fluid of celecoxib treated mice
versus control and SC-560 treated mice (p,0.05). There were no
significant differences between the groups in percentages of
different cell type at either timepoint (Table 1).
Lung Viral Titres
Virus was detectable in the lungs of all three groups on day 1 of
infection (Figure 5). By day 4, viral titres had markedly increased.
There were no significant differences between the three groups on
either day.
BAL fluid and serum cytokines
On day 1 post-infection, all cytokines tested, with the exception
of IL-1b, were detectable and there were no significant differences
between the three groups (Table 2). By day 4, there was a marked
elevation in BAL fluid cytokine levels in all three groups. There
were no significant differences between the groups in the BAL
fluid levels of MCP-1, IL-1b, IFN-c, IL-12p40 or MIP-1a. BAL
fluid levels of TNF-a and G-CSF were significantly attenuated in
the SC-560 and celecoxib treated groups versus control. The
chemokine KC was also significantly lower in the SC-560 treated
group versus control. In addition, BAL fluid levels of IL-6 were
significantly lower in celecoxib treated mice versus control. Similar
to BAL fluid, levels of G-CSF in serum on day 4 were significantly
lower in the celecoxib treated group versus control; there was a
trend for reduced levels in the SC-560 treated group versus control
on day 5. There were no significant differences between the groups
in serum levels of other cytokines (Table 2). Taken together, these
data demonstrate that the increased morbidity and mortality in
COX-1 inhibitor treated mice is accompanied by reduced BAL
fluid levels of pro-inflammatory cytokines and chemokines.
Inhibitor treatment had less of an effect on circulating cytokine
levels compared to BAL fluid cytokine levels.
Figure 1. Mortality following influenza A viral infection in control (n=30), SC-560 (n=19) and celecoxib (n=19) treatment groups;
*p,0.05 versus control, ‘ p,0.05 versus celecoxib.
doi:10.1371/journal.pone.0011610.g001
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treatment groups. Numbers of mice in each group and timepoint are shown in the table. Data represent mean 6 SEM; *p,0.05 versus control.
doi:10.1371/journal.pone.0011610.g002
Figure 3. Time course of body weight changes following influenza A viral infection in control, SC-560 and celecoxib treatment
groups. Numbers of mice in each group and timepoint are shown in the table. Data represent mean 6 SEM; *p,0.05 versus control.
doi:10.1371/journal.pone.0011610.g003
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The present study examined the effects of treatment with a
COX-1 or COX-2 selective inhibitor on the host response to
influenza A viral infection in mice. Treatment with the COX-1
selective inhibitor SC-560 was associated with greater mortality
and greater infection-induced changes in body temperature and
body weight compared to treatment with the COX-2 selective
inhibitor celecoxib or no inhibitor (control). Numbers of
inflammatory cells in the BAL fluid were increased in the
celecoxib treated group compared to the SC-560 and control
groups. Inhibition of either COX enzyme led to decreases in BAL
fluid levels of TNF-a and G-CSF. In contrast only inhibition of
COX-1 led to a decrease in BAL fluid levels of KC and only
Figure 4. BAL fluid cellularity on days 1 and 4 of infection in control, SC-560 and celecoxib treatment groups. Data represent mean 6
SEM (n=16–17 per group and timepoint). *p,0.05 versus control, ‘ p,0.05 versus SC-560.
doi:10.1371/journal.pone.0011610.g004
Table 1. Percentage cellular compostion of BAL fluid.
Neutrophils Lymphocytes Eosinophils Macrophages
Day 1 Control 15652 601 618 2 65
SC-560 15643 612 618 0 64
Celecoxib 13633 612 618 2 64
Day 4 Control 40656 610 605 4 65
SC-560 32656 610 606 2 65
Celecoxib 43657 611 604 9 64
N=16–17 per group per timepoint; data shown are mean 6 SEM; no significant differences between treatment groups for each timepoint.
doi:10.1371/journal.pone.0011610.t001
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were similar between the treatment groups.
We previously demonstrated a biphasic temperature response to
influenza viral infection in mice — an initial hyperthermic
response followed by a progressive hypothermic response [11].
Mice and other small rodents tend to develop hypothermia rather
than fever in response to infectious stimuli [15]. In the present
study, inhibition of either COX-1 or COX-2 blocked the initial
hyperthermic response. Subsequently, inhibition of COX-1 led to
profound hypothermia whereas inhibition of COX-2 led to a
normal hypothermic response. These results contrast with
observations in COX-deficient mice in that COX-1 deficiency
led to a greater hyperthermic response and COX-2 deficiency
abrogated the development of hypothermia [11]. The present
findings are similar to the prior study with knockout mice in that
COX-2 deficiency abolished the hyperthemic response and COX-
1 deficiency worsened the degree of hypothermia. Considerable
evidence supports the role of COX enzymes in thermoregulation.
COX-2 has predominantly been implicated in modulating body
temperature changes in response to infection. However, some
studies have also implicated COX-1. Studies in rats have shown
that LPS-induced hypothermia is blocked by the COX-1
inhibitors SC-560 [16,17] and valeryl salicylate [16], but enhanced
by the COX-2 inhibitor SC-236 [17]. In contrast, an earlier study,
also in rats, found that the COX-2 inhibitor SC-236 blocked LPS-
induced hyperthermia but that the COX-1 inhibitor SC-560
resulted in profound hypothermia in response to LPS [18]. The
results of the latter study are consistent with the observations of the
current study.
A critical challenge for the immune system is balancing the
immune response to control infection while minimizing damage to
the host. It is thought that much of the morbidity and mortality
associated with influenza infection can be attributed to an over
exuberant immune response leading to excessive production of
cytokines and excessive inflammation at the site of infection [5,19–
21]. Indeed, when we examined the response to influenza A virus
in the COX deficient mice, clinical signs of infection correlated
with the inflammatory response [11]. Inflammation was reduced
Table 2. BAL fluid and serum cytokine/chemokine levels (pg/ml).
Test material Analyte Day 1 Day 4
Control SC-560 Celecoxib Control SC-560 Celecoxib
BAL fluid MCP-1 14610 12642 61 691685 638694 679689
IL-1b 0600 600 606 613 615 61
IFN-c 1601 601 605 614 614 61
TNF-a 4614 624 614 9 610 2964* 3365*
IL-6 6642 601 60 271643 248658 145618*‘
IL-12p40 6619 621 5 66 5916123 5296101 538698
G-CSF 5624 614 61 387655 203631* 253646*
KC 7621 1 621 2 63 101613 70611* 87611
MIP-1a 25692 6 661 6 659 1 615 74615 89613
Serum MCP-1 304641 315622 318631 307615 306628 353643
IL-1b 16632 2 682 6 672 5 662 4 621 5 64
IFN-c 166623 200634 206635 153622 149632 228657
TNF-a 6366102 8006191 814699 7696149 522694 7516160
IL-6 43674 0 643 9 645 8 684 3 644 5 65
IL-12p40 471648 516692 5976165 652694 446673 618668
G-CSF 103612 101697 6 69 187619 139616 126616*
KC 70614 56695 2 611 174641 123617 93612
MIP-1a 413674 5256153 500695 4986106 580672 437695
n=10–17 per group per timepoint; data shown are mean 6 SEM.
*p,0.05 vs. Control Day 4.
‘p,0.05 vs. SC-560 Day 4.
doi:10.1371/journal.pone.0011610.t002
Figure 5. Lung viral titres on days 1 and 4 of infection. Data
represent mean 6 SEM (n=8–10 per group and timepoint). Differences
between the three treatment groups are not statistically significant;
however, viral titres on day 4 are significantly higher than on day 1 for
each group.
doi:10.1371/journal.pone.0011610.g005
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morbidity. In contrast, inflammation in COX-1 deficient mice
was enhanced and this was associated with a poorer clinical
outcome. Surprisingly, in the present study clinical signs of
infection in the COX inhibitor treated mice did not correlate with
inflammation. The celecoxib treated group had mildly elevated
levels of inflammatory cells in the BAL fluid and several pro-
inflammatory cytokines remained unchanged whereas others were
reduced compared to the control group. There was little difference
between the celecoxib treated and control groups with respect to
clinical signs. In contrast, SC-560 treatment had no significant
effect of BAL fluid inflammatory cell numbers, although there was
a trend for decreased neutrophils which may be related to the
depressed levels of the neutrophil chemokine KC on day 4 of
infection. Otherwise, SC-560 treatment produced a very similar
BAL fluid cytokine profile to celecoxib treatment. Yet, the SC-560
group exhibited more severe clinical signs of illness and 100%
mortality. These results suggest that inflammation can be
dissociated from clinical outcome in the COX inhibitor treated
animals.
In addition to immune system activation, inflammatory or
infectious stimuli induce a highly coordinated central nervous
system response which modulates body temperature changes. The
COX-1 inhibitor induced profound hypothermia in influenza
infected mice suggesting that COX-1 is required for the
suppression of hypothermia following infection with influenza in
mice. The degree of hypothermia in mice can predict mortality:
when body temperature drops below a certain point in various
infection models, death is almost inevitable [22,23]. It is difficult to
say definitively whether the hypothermia was the cause of
excessive mortality in the SC-560 or a consequence/marker of
some other process.
The mechanisms regulating hypothermia are not fully under-
stood but cytokines such as TNF-a and interleukins have been
shown to induce or modulate the hypothermic response [24].
Studies have shown that the degree of hypothermia correlates with
levels of certain pro-inflammatory cytokines [25]. We did not
observe any elevation in cytokine levels in the SC-560 treated
group relative to control that might explain the excessive
hypothermia; cytokines examined were either unchanged or
blunted in relation to control.
The differential effects of SC-560 on the temperature response
may in fact be mediated further upstream in the process (i.e.
centrally in the brain). Several studies support a role of COX
products in the central nervous system response to infectious
stimuli. For example, microinjection of a COX inhibitor into the
preoptic area of rat brain, a region believed to be responsible for
thermoregulation, decreased the fever response to LPS suggesting
that prostaglandin biosynthesis in that region of the brain is
necessary to modulate the thermoregulatory response to infection
[26]. PGE2 produces fever when injected intracerebroventricularly
[27] and mice lacking the EP3 receptor also lacked an appropriate
febrile response to PGE2 [28]. Oka and colleagues found that the
EP3 receptor is necessary to produce fever and also necessary to
prevent profound hypothermia in response to LPS [29]. The
effects of COX inhibitors on the brain circuitry that is activated as
part of the thermoregulatory response to infection in mice have
not been thoroughly investigated and would be an interesting area
for future study.
Treatment of influenza A virus infected mice with selective COX
inhibitors did not recapitulate the phenotypes observed using the
same model in COX knockout mice. This is not a unique
observation: we have previously observed discordance between
studies with COX knockout mice and COX inhibitor treated mice
in an allergic airway disease model [10,30]. There are several
potential explanations for the discordance. First, in inhibitor studies,
the COX enzymes are inhibited at the time of study, whereas COX
knockout mice are genetically deficient in the enzyme from the
point of conception. Second, the COX knockout mice have a total
absence of the respective COX activity, a condition likely not
attainable, even with higher doses of COX inhibitors [31]. Third,
the COX enzymes are known to play differential roles in immune
development [12,13] and thus immune phenotypes of the COX
knockout mice may be a consequence of developmental effects of
COX deficiency rather than inhibition of the enzyme. Finally, it is
alsopossiblethatsomeofthediscordancebetweentheknockoutand
inhibitor studies could be due to COX-independent effects of the
inhibitors [32,33].
An interesting observation was that treatment with either COX
inhibitor led to depressed levels of G-CSF in BAL fluid on day 4 of
infection and a similar trend was observed in serum. G-CSF
expression is often induced during infection and is thought to play
an important role in the regulation of the systemic and local
neutrophil response to the infection [34], a process known as stress
or emergency granulopoiesis. However, the depressed levels of G-
CSF in the COX inhibitor treated groups appear not to have
significantly affected BAL fluid neutrophil levels; in fact, neutrophils
were slightly elevated on day 4 in the celecoxib treated group. It is
possible that the importance of G-CSF in regulating stress
granulopoiesis is pathogen/route dependent: in G-CSF null mice,
neutrophilia is normal in response to intravenous Candida albicans or
intraperitoneal Listeria monocytogenes but blunted in response to
intravenous Listeria monocytogenes [35–37]. Nevertheless, the obser-
vation that COX inhibitors can depress G-CSF levels during stress
granulopoiesis is important and may have significant consequences
in other infectious models/states.
The COX enzymes are a major pharmaceutical target. Because
of their analgesic effects and their potent anti-inflammatory and
anti-pyretic properties, NSAIDs are amongst the most widely
prescribed drugs in the western world. The classical NSAIDs
inhibit both COX-1 and COX-2 but tend to be more selective
towards COX-1 [38]. While one cannot extrapolate from animal
studies directly to human populations, the profound effect of the
COX-1 inhibitor SC-560 on the thermoregulatory response to
influenza A virus is noteworthy and deserves more detailed study.
A key focus of future studies will be to examine how the
thermoregulatory response in the brain of influenza A virus
infected mice is modulated by SC-560 and other COX inhibitors.
In the present study the COX inhibitors were administered
orally and in chow given ad libitum. As we observed, the model was
characterized by weight loss and so it is possible that mice were not
receiving a consistent dose of drug each day. Nevertheless, the fact
that the COX-1 inhibitor had such a profound effect with the
greatest weight loss suggests the COX-1 is critical to host response
to influenza viral infection and can still have a potent, long lasting
effect, even at lower doses.
In summary, we have shown that treatment with a COX-1
inhibitor during influenza A viral infection is detrimental to the
host, whereas treatment with a COX-2 selective inhibitor does not
significantly modulate disease severity. Furthermore, our studies
point to a critical role for COX-1 in controlling the thermoreg-
ulatory response to influenza infection in mice.
Materials and Methods
Animals and drug treatments
All animal studies were conducted in accordance with principles
and procedures outlined in the National Institutes of Health Guide
COX Inhibitors in Influenza
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by the Animal Care and Use Committee at the National Institute
of Environmental Health Sciences (NIEHS) (Protocol 06-08 LRB,
assurance number A4149-1). Female, pathogen-free, 3–5 mo old
mice were of a hybrid C57BL/6J6129/Ola genetic background
bred at Taconic Farms. They were housed under identical
conditions and fed NIH 31 rodent chow (Agway) ad libitum. NIH-
31 rodent chow was formulated into meal containing either
1500 ppm of the COX-2 selective inhibitor celecoxib (LKT
laboratories, St. Paul, MN), 20 ppm of the COX-1 selective
inhibitor SC-560 (Cayman Chemical, Ann Arbor, MI) or no
inhibitor at Research Triangle Institute (Research Triangle Park,
NC). Mice were fed control or COX-inhibitor containing diet ad
libitum beginning 2 weeks prior to infection and continuing
through the duration of each experiment. Previous studies have
demonstrated that similar doses of COX inhibitors are well
tolerated and result in selective inhibition of the respective COX
isoforms in mice [39].
Influenza infection model (Figure 6)
Two weeks following the initiation of COX inhibitor treatment
(day 0), mice were weighed and rectal temperatures were recorded
electronically (Thermalert TH-5; Physitemp). A frozen aliquot of
influenza A/Hong Kong/8/68 (H3N2) was used to prepare
dilutions in HBSS containing 200 PFU in 50 ml. The virus was a
generous gift from Dr. R. Luebke (U.S. Environmental Protection
Agency, Research Triangle Park, NC). Mice were lightly
anesthetized with isofluorane and infected by intranasal instillation
of 25 ml/nostril. There were 2 experimental groups:
Group 1: BAL was performed on days 1 or 4 post-infection for
the measurement of BAL fluid cells, cytokines and viral titres
(Figure 6A)
Group 2: Daily body temperature, body weight and mortality
were recorded up to 2 weeks post-infection (Figure 6B).
Bronchoalveolar lavage (BAL) fluid and serum processing
and analysis
Mice were anesthetized by i.p. injection of sodium pentobarbital
(80 mg/kg). A blood sample was drawn from the abdominal aorta.
Serum was extracted, frozen and stored at 280uC. Lungs were lavaged
with two 1-ml aliquots of HBSS that were subsequently combined.
Approximately 90% of the total instilled volume was consistently
recovered. The BAL fluid was placed on ice and centrifuged at 3606g
for 10 min at 4uC. Aliquots of BAL fluid for cytokine analyses were
stored at 280uC. Cells were resuspended in 1 ml of HBSS and
counted using a Coulter counter (Z1 model;CoulterElectronics).Slides
of BAL fluid cells were prepared (Cytospin 3; Shandon), stained with
Wright-Giemsa (Fisher Scientific), and differentiated using conven-
tional morphological criteria in a blinded fashion. Cytokine levels in
BAL fluid and serum were determined with a Bio-Plex mouse cytokine
kit (Bio-Rad, Hercules, CA) using fluorescently-labeled microsphere
beads and a Bio-Plex suspension array system (Bio-Rad) according to
the manufacturer’s instructions.
Pulmonary virus quantitation
On days 1 and 4 of infection, lungs were homogenized in ice-
cold HBSS (10% w/v). The homogenates were centrifuged at
10006g for 30 min to remove cell debris and the supernatants
were stored at 280uC until assay. The tissue culture ID50
(TCID50) of virus in the lungs was determined as previously
described [11]. Briefly, confluent monolayers of Madin-Darby
canine kidney cells on 96-well microtiter plates were infected with
one-half log10 dilutions of lung homogenates. After 3–4 days of
incubation at 37uC, the wells were observed for cytopathic effect.
Figure 6. Overview of study design. (A) Inflammatory endpoints. (B) Clinical endpoints.
doi:10.1371/journal.pone.0011610.g006
COX Inhibitors in Influenza
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was calculated according to the Reed-Muench method [40].
Statistical analyses
R e s u l t sa r ee x p r e s s e da sm e a n s6 SEM. Groups were compared
by ANOVA followed by multiple comparison of means with
Newman-Keuls multiple comparison test. An unpaired t-test was
used when groups of only two were being compared. Survival was
analyzed using the x
2 test with Fisher’s exact method. All statistics
were performed using GraphPad Prism (version 4) statistical software
(GraphPad Software). Values of p,0.05 were considered significant.
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